Stock Events

Stock Events

Search...

Strategic Partners A/S

€137.5

0

-€4-2.83% Wednesday 07:08

Statistics

Day High

137.5

Day Low

137.5

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

20AugExpected

Q4 2023

Q2 2024

999

333

-333

-999

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1TB0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen is a biotech firm with a strong focus on neurodegenerative diseases, similar to Orphazyme's focus on rare diseases.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is involved in treating cystic fibrosis, a rare disease, showing its capability and interest in the rare disease market.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, aligning with Orphazyme's rare disease treatment goals.

Sarepta Therapeutics

Sarepta Therapeutics specializes in the treatment of rare genetic diseases, particularly in the area of Duchenne muscular dystrophy.

Ionis Pharmaceuticals

Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, working on treatments for rare diseases.

Biomarin Pharmaceutical

BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the same rare disease space as Orphazyme.

CRISPR Therapeutics

CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat the genetic roots of many rare diseases.

bluebird bio focuses on gene therapies for genetic diseases and cancer, competing in the rare disease treatment space.

Novo Nordisk, while known for diabetes care, is expanding into treatments for rare blood disorders, showing its growing interest in the rare disease sector.

Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the rare disease market space.

About

Orphazyme A/S does not have significant operations. Previously, it was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is based in Herlev, Denmark.

Show more...

CEO

Mr. Jakob Færch Bendtsen

Employees

1

Country

Denmark

ISIN

DK0062502894

WKN

000A3EYNB

Listings